30
November
2014

Enzalutamide available on the PBS

Enzalutamide available on the PBS

From 1 December 2014, a new drug for advanced prostate cancer will be available and listed on the PBS. Enzalutamide is an oral drug used for advanced prostate cancer (metastatic castration resistant prostate cancer). It works by inhibiting binding of androgens (such as testosterone) to the androgen receptor (AR), as well as inhibiting the AR from entering the cell nucleus and from binding to DNA. It has had encouraging results in clinical trials.


What are the PBS criteria for enzalutamide?

The treatment cannot be used in combination with chemotherapy (docetaxel in the common chemotherapy agent used in advanced prostate cancer)

AND

The patient must have failed treatment with docetaxel due to resistance (this generally means progression of disease or non-response to docetaxel) or intolerance

OR

The patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel

AND

Patient must have a World Health Organisation Performance Status of 2 or less (this means good performance)

AND

The patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug

AND

The patient must not have received prior treatment with abiraterone

OR

Patient must have developed intolerance to abiraterone of a severity necessitating permanent withdrawal of abiraterone.

Categories: Updates, Prostate Cancer

Nick Brook

Comments (0)

Leave a comment

You are commenting as guest.

Affiliations

Urology Affiliations

Latest Tweets

Contact Us

  • Nick Brook Urology
    Kimberley House
    89 Strangways Tce,
    North Adelaide,
    Adelaide SA 5006
  • 08 8463 2500
  • 08 8267 3684